The present disclosure provides delivery vectors for expressing a chimeric receptor in a monocytic cell, such as a macrophage or dendritic cell. The chimeric receptor may specifically bind to a particular antigen or target molecule, such as an immune checkpoint protein or OX40. The disclosed delivery vectors can be used to treat cancer in a subject by expressing in vivo a chimeric receptor on the surface of the subject's monocytic cells.

Pharmaceutical compositions, in particular vaccine compositions, for preventing or at least reducing the severity of, respectively, viral respiratory infections through application of said composition to a human subject post-exposure or at least presumed post-exposure of said subject to a virus causing said viral respiratory infections or pre-exposure of said subject to said virus. More particularly, in specific embodiments, the invention provides pharmaceutical compositions as such comprising at least one antigenic component of the infectious virus and a TLR-3 agonist. The invention also relates to methods of treatment and/or prevention of said viral respiratory infections through administration of the composition to the human subject post exposure or at least presumed post-exposure of said subject to the infectious virus or pre-exposure of said subject to said virus

Described herein are constructs, compositions and methods for precise in vivo imaging of the structures and dynamics of protein-based scaffolds with and without their designated cargos.

In order to provide an antibody having high therapeutic and prophylactic effects against cancer and the like, three types of mouse monoclonal antibodies were prepared which exhibit high affinities for a human-derived Eva1 protein. Moreover, constant regions of these antibodies were substituted with human-derived constant regions to also prepare chimeric antibodies. Further, these mouse antibodies and chimeric antibodies were found to have high ADCC and/or CDC activities. Furthermore, it was also revealed that administering these antibodies to mice having been subjected to melanoma cell administration suppresses the metastasis and the like of the cells to the lungs.

Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.

Aspects of the present disclosure relate to genetically altered plants with enhanced biomass including genetic alterations that stimulate RubP regeneration and electron transport. In particular, the present disclosure relates to genetically altered plants with enhanced biomass through overexpression of CB proteins (e.g., FBPase/SBPase or SBPase), and overexpression of photosynthetic electron transport proteins (e.g., cytochrome c.sub.6 and Rieske FeS).

Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads have dual functionality that may permit treatment of diseases in a subject other than diseases that present in the brain, e.g., solid tumors in the body. Methods of treating various diseases and pharmaceutical compositions are also disclosed.

The invention, in some aspects, relates to polypeptide molecules and their encoding nucleic acid molecules and use of such molecules to target opsins to the soma of cells in which they are expressed. Compositions of the invention may be delivered to cells and subjects and used in methods to modulate electrical activity of cells in which they are expressed, and for treatment of diseases and conditions in subjects.

The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.